Continuous treatment in Finland Martta Forsell, the Finnish Focal Point 10/11/2018 Martta Forsell

Data collection in Finland Voluntary for the treatment centers Separate client questionnaire, not (yet) part of electronic patient record. When entering treatment If client continues in treatment, new questionnaire in January (or springtime..) Covers an estimated one third of the drug-related treatment In 2012, 85 units providing drug-related treatment participated in the information collecting, submitting data on 2,688 clients. No obvious biases 10/11/2018 Esityksen nimi / Tekijä

Finnish National Treatment Data 2012 (n= 2 688) our method and the key concerns we have. 10 minutes, 5 slides. How does that sound? 10/11/2018 Martta Forsell

Finnish National Treatment Data 2012 (n= 2 688) 10/11/2018 Esityksen nimi / Tekijä

Finnish National Treatment Data 2012 10/11/2018 Esityksen nimi / Tekijä

Esityksen nimi / Tekijä Length of the treatment (in years since start of treatment) on continuous treatment 10/11/2018 Esityksen nimi / Tekijä

Esityksen nimi / Tekijä Length of the treatment as ‘episodes’ (columns) and the OST for clients (black) 10/11/2018 Esityksen nimi / Tekijä

Renewed questionnaire 2014 onwards The Finnish survey and guidelines needed improving + TDI 3.0 The questionnaire has been revised 2012-2013 and fully renewed questionnaire will be implemented 2014. Will be 100% TDI 3.0 compatible Rethinking on (among others) ‘primary drug’ on continuous treatment Continuous treatment in an in-patient facility OST information More ‘re-launch’ than ‘fine-tuning’. Overall aims: better data quality better coverage better understanding of the coverage 10/11/2018 Esityksen nimi / Tekijä

Esityksen nimi / Tekijä Primary drug Defining the primary drug at the start of treatment is straight forward enough But on continuous treatment the primary problem can change 10/11/2018 Esityksen nimi / Tekijä

Esityksen nimi / Tekijä THEN NOW Primary drug? Primary drug? Secondary drug? Route of admistration? Frequency? Intrest on treatment inputs Intrest on epidemiology 10/11/2018 Esityksen nimi / Tekijä

Primary drug Secondary drug - route -frequency THEN NOW Primary drug Secondary drug - route -frequency Primary & secondary drug Route Frequency 10/11/2018 Esityksen nimi / Tekijä

Primary (secondary) drug in Finland from 2014 onwards Primary drug now (~30 days prior entering treatment) OR Long-standing problem drug which contributed to the entering treatment or is emphasized in the current treatment ~ drug the client is addicted to (whether at the moment active drug use) The OST clients are always addicted > opioid as long-standing drug Frequency is always the very last 30 days (except in-patient..) 10/11/2018 Esityksen nimi / Tekijä

Esityksen nimi / Tekijä In-patient client Enters treatment 1.Dec Questionnaire: use of drugs in Nov New questionnaire in Jan: use of drugs in Nov > the copy of previous questionnaire Client checks out in Feb New questionnaire in Feb in an out-patient facility: use of drugs in Jan-Feb 10/11/2018 Esityksen nimi / Tekijä

Primary (secondary) drug in Finland from 2014 onwards Primary drug now (~30 days prior entering treatment) OR Long-standing problem drug which contributed to the entering treatment or is emphasized in the current treatment ~ drug the client is addicted to (whether at the moment active drug use) The OST clients are always addicted > opioid as long-standing drug Frequency is always the very last 30 days (except in-patient..) NO more in-patient continuous questionnaire 10/11/2018 Esityksen nimi / Tekijä

Primary (secondary) drug in Finland from 2014 onwards Primary drug now (~30 days prior entering treatment) OR Long-standing problem drug which contributed to the entering treatment or is emphasized in the current treatment ~ drug the client is addicted to (whether in remiss or not) Which we should put forward as we report the primary drug for the EMCDDA? 10/11/2018 Esityksen nimi / Tekijä